Jody A. Charnow, Editor

Jody A. Charnow, Editor

Jody Charnow is the editor of Renal and Urology News.

Most Recent Articles by Jody A. Charnow, Editor

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

By

Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

By

Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

By

Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

By

About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

By

Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.

More Articles by Jody A. Charnow, Editor

Sign Up for Free e-newsletters